CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials.

ABSTRACT: Even though chemotherapy and immunotherapy emerged to limit continual and unregulated proliferation of cancer cells, currently available therapeutic agents are associated with high toxicity levels and low success rates. Additionally, ongoing multi-targeted therapies are limited only for few carcinogenesis pathways, due to continually emerging and evolving mutations of proto-oncogenes and tumor-suppressive genes. CRISPR/Cas9, as a specific gene-editing tool, is used to correct causative mutations with minimal toxicity, but is also employed as an adjuvant to immunotherapy to achieve a more robust immunological response. Some of the most critical limitations of the CRISPR/Cas9 technology include off-target mutations, resulting in nonspecific restrictions of DNA upstream of the Protospacer Adj

SUBMITTER: Khalaf K 

PROVIDER: S-EPMC7463827 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature